Galecto (GLTO) Soars on Damora Therapeutics Acquisition and $285M Financing: IND in 2026, Proof‑of‑Concept in 2027

Galecto, Inc. (NASDAQ: GLTO) said this morning it completed the acquisition of Damora Therapeutics and closed a $284.9 million oversubscribed private placement, a one‑two punch that instantly refocuses the company on mutant calreticulin (mutCALR) therapies for myeloproliferative neoplasms (MPNs) and extends its cash runway into 2029. The announcement sent GLTO screaming higher in pre‑market trading. ^[1]

Key takeaways

• Deal closed: Galecto acquired privately held Damora Therapeutics; no GLTO shareholder vote required. ^[2]
• Fresh capital:$284.9M gross proceeds via Series C non‑voting convertible preferred round led by Fairmount; participants include Viking Global, Wellington, RA Capital, a16z Bio + Health, BB Biotech, Venrock and others. Runway into 2029. ^[3]
• Pipeline pivot: Damora’s DMR‑001, a subcutaneous, anti‑mutCALR monoclonal antibody for ET and MF, targets a driver mutation present in ~25% of ET and 35% of MF patients; IND mid‑2026, Phase 1 proof‑of‑concept data in 2027. ^[4]
• Stock reaction: GLTO jumped ~285% pre‑market, with some feeds showing even larger spikes during early indications. ^[5]

Why this matters for patients and investors

Damora’s approach is aimed squarely at mutant calreticulin (mutCALR)—a well‑validated genetic driver in segments of essential thrombocythemia (ET) and myelofibrosis (MF). Targeting this neoantigen has attracted growing interest as researchers seek more disease‑modifying options beyond today’s largely symptom‑managing therapies. Early clinical work from other groups has already shown that mutCALR‑specific antibodies can inhibit oncogenic signaling without harming normal hematopoiesis, underscoring the potential for the class. ^[6]

Galecto says DMR‑001 has shown ~10‑fold greater potency in preclinical Type 2 mutCALR models versus an internal reference molecule in development, and it’s engineered for infrequent, low‑volume subcutaneous dosing—a convenience angle that could matter to chronic‑disease patients. An IND filing is planned for mid‑2026 with first‑in‑human dosing to follow; Phase 1 proof‑of‑concept is targeted for 2027. ^[7]

The deal and financing, in brief

• Transaction: Acquisition of Damora Therapeutics (privately held).
• Financing:$284.9M private placement (Series C non‑voting convertible preferred) led by Fairmount; investors include Viking Global Investors, Wellington Management, RA Capital Management, TCGX, Forbion, Perceptive Advisors, Balyasny, Andreessen Horowitz (a16z Bio + Health) and others. Proceeds are expected to fund operations into 2029. ^[8]
• Share count & governance: Following the transactions, 61,998,882 GLTO common shares will be outstanding on an as‑converted basis (subject to beneficial ownership limits). New board members from Fairmount—Peter Harwin, Chris Cain, PhD, and Julianne Bruno—join Galecto’s board.

Market reaction

GLTO was among the market’s biggest pre‑market movers. TipRanks cited a ~285% surge ahead of the open, while MarketBeat showed extended‑hours quotes above $17 per share around 8:06 a.m. ET, up more than +240% from Friday’s close (regular‑hours charts may not reflect pre‑market).

Note: The price chart above reflects official trade prints and may exclude some pre‑market moves.

What’s in the combined pipeline?

• DMR‑001 (Damora): Anti‑mutCALR mAb for ET/MF; IND mid‑2026, PoC 2027; designed for subcutaneous dosing.
• DMR‑002 / DMR‑003 (Damora): Preclinical mutCALR‑targeted programs slated to enter Phase 1 with the extended runway.
• GB3226 (Galecto): Dual ENL‑YEATS/FLT3 inhibitor for AML; pre‑IND feedback received; IND planned for Q1 2026; two ASH 2025 posters next month (Dec. 6–9, Orlando).

Why mutCALR? mutCALR drives abnormal JAK‑STAT signaling through aberrant TPO‑R activation in a sizeable subset of MPNs, and selective antibodies have emerged as a rational therapeutic strategy.

Competitive context

mutCALR is an increasingly active arena. For instance, academic and industry groups have presented mutCALR‑specific antibody data in ET/MF, helping to validate the target biologically and clinically. Damora’s claim of higher preclinical potency and patient‑friendly dosing sets up a clear, testable differentiation thesis as programs advance into the clinic.

Timeline and catalysts to watch

• Today (Nov. 10):Galecto webcast at 8:00 a.m. ET to discuss the deal and pipeline. A replay will be posted on the Investors site.
• Q1 2026:GB3226 IND submission (AML).
• Mid‑2026:DMR‑001 IND submission; first‑in‑human dosing thereafter.
• 2027:Phase 1 PoC readout for DMR‑001 in mutCALR‑driven ET/MF.

The bottom line

With Damora on board and $285M in fresh capital, Galecto has repositioned itself around a hot MPN target with clear clinical milestones on the horizon. The scientific rationale for mutCALR is strong, the subcutaneous profile is patient‑friendly, and the funding runway to 2029 reduces near‑term financing risk. Near‑term volatility in GLTO shares is likely, but the story from here will be written by IND clearances and first‑in‑human data over the next 18–24 months.

Sources

• Galecto press release: “Galecto Announces Acquisition of Damora Therapeutics,” Nov. 10, 2025.
• StockTitan summary of Galecto release.
• TipRanks: “Why Is Galecto Stock (GLTO) Up 285% Today?” (pre‑market move).
• MarketBeat GLTO extended‑hours snapshot (pre‑market indication).
• Damora Therapeutics site (mutCALR focus and disease background).
• Scientific background on mutCALR in ET/MF.

This article is for information purposes only and is not investment advice.

References

1. www.globenewswire.com, 2. www.globenewswire.com, 3. www.globenewswire.com, 4. www.globenewswire.com, 5. www.tipranks.com, 6. pmc.ncbi.nlm.nih.gov, 7. www.globenewswire.com, 8. www.globenewswire.com